Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes.

Annals of neurology·2026
Same author

Are Traditional Registries Becoming Obsolete in the Modern Digital Health Ecosystem?

Journal of medical Internet research·2026
Same author

Exploring attitudes and acceptance of artificial intelligence in multiple sclerosis from the patient perspective.

PLOS digital health·2026
Same author

Brain age gap in multiple sclerosis: associated with disability but independent of serum biomarkers.

Therapeutic advances in neurological disorders·2026
Same author

Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial.

Health technology assessment (Winchester, England)·2026
Same author

Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study.

European journal of neurology·2026

Related Experiment Video

Updated: Sep 1, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.1K

MSProDiscuss™ Clinical Decision Support Tool for Identifying Multiple Sclerosis Progression.

Tjalf Ziemssen1, Jo Vandercappellen2, Valeria Jordan Mondragon2

  • 1Center of Clinical Neuroscience, Department of Neurology, Carl Gustav Carus University Clinic, Fetscherstraße. 74, 01307 Dresden, Germany.

Journal of Clinical Medicine
|August 12, 2022
PubMed
Summary

A new clinical decision support tool, MSProDiscuss™, aids neurologists in identifying multiple sclerosis (MS) progression early. It analyzes patient data to personalize treatment and improve care for those with this progressive neurological disease.

Keywords:
MS progressionMSProDiscussRRMSSPMSclinical decision support toolmultiple sclerosis

More Related Videos

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.8K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.2K

Related Experiment Videos

Last Updated: Sep 1, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.1K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.8K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.2K

Area of Science:

  • Neurology
  • Clinical Informatics
  • Digital Health

Background:

  • Multiple sclerosis (MS) is a progressive neurological disease with varied symptoms and disease courses.
  • Neuroaxonal loss and progression can occur early and independently of inflammatory relapses.
  • There is a need for tools to assist clinicians in detecting subtle signs of MS progression.

Purpose of the Study:

  • To describe the rationale and development of the MSProDiscuss™ clinical decision support (CDS) tool.
  • To explain how MSProDiscuss™ can help neurologists enhance care for patients with multiple sclerosis.
  • To provide insights into utilizing CDS tools for improved MS management.

Main Methods:

  • The MSProDiscuss™ tool was developed collaboratively with neurologists and patients.
  • It employs an algorithm to analyze multidimensional patient data.
  • The tool estimates the likelihood of MS progression (MSProDiscuss score), symptom contribution, and impact on daily living.

Main Results:

  • MSProDiscuss™ facilitates a structured approach to patient consultations.
  • It enables personalized treatment and disease management strategies.
  • Data from the tool offer insights into MS disease course and support informed decision-making.

Conclusions:

  • The MSProDiscuss™ CDS tool assists neurologists in identifying early signs of multiple sclerosis progression.
  • It promotes a more personalized and holistic approach to managing MS patients.
  • Utilizing such tools can lead to improved patient outcomes and informed clinical decisions.